-Tehelka.com There are few figures from the adivasi community in India who have made a bigger dent in the collective imagination of the country than Dayamani Barla. The "iron lady of Jharkhand" has been instrumental in articulating adivasi struggles against displacement and deprivation on national and international platforms. Dayamani, who was recently imprisoned in Jharkhand for her involvement in the Nagri people's movement, has won the first Ellen L Lutz Indigenous...

-The Times of India MUMBAI: It's widely known that a month's dose of cancer drugs can cost lakhs, but what isn't common knowledge is that Tata Memorial Hospital's doctors are working on alternatives that could cost less than Rs 1,000 a month. Dubbed the metronomic treatment protocol, it comprises daily consumption of a combination of low-dose medicines that are cheap because they have been around for decades. "There is no need to...

-The Telegraph Imphal: A Manipuri widow's cry for justice rang out during the 23rd session of the UN Human Rights Council this morning, as she questioned gaps in UN Special Rapporteur on extrajudicial, summary or arbitrary executions Christof Heyns's report on the Armed Forces (Special Powers) Act. Neena Ningobam, who represented the Extrajudicial Execution Victim Families' Association, Manipur, of which she is the secretary, and the Asian Legal Resource Centre (ALRC) at...

-The Hindu Aruna Roy's decision to terminate her relationship with the Sonia Gandhi-led National Advisory Council has returned the spotlight to the ideological divide within the ruling establishment on welfare spending. As the civil rights activist noted in her letter to the Congress president, the rupture came over the Manmohan Singh government's refusal to pay statutory minimum wages to workers under the Mahatma Gandhi National Rural Employment Guarantee Act -...

-The Economic Times Japanese companies do not mind erring on the side of caution. They are known to think longer and harder than their counterparts in other countries about big decisions, especially when it comes to entering a new market or acquiring a foreign company. But Japan's third biggest drugmaker Daiichi Sankyo would now wish it had spent more time doing due diligence on Ranbaxy Labs, in which it bought a...